Sansure Biotech(688289)2024-07-03 11:28Financial Performance - The company expects to achieve operating revenue of 710 million yuan for the first half of 2024, an increase of 282.30 million yuan, representing a year-on-year growth of 66%[2]. - The estimated net profit attributable to the parent company for the first half of 2024 is between 150 million yuan and 165 million yuan, an increase of 58.32 million yuan to 73.32 million yuan, reflecting a year-on-year growth of 64% to 80%[2]. - The projected net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 120 million yuan and 130 million yuan, an increase of 88.82 million yuan to 98.82 million yuan, indicating a year-on-year growth of 285% to 317%[2]. - In the same period of the previous year, the company achieved operating revenue of 427.70 million yuan and a net profit of 91.68 million yuan[3]. Strategic Initiatives - The company is implementing an innovation-driven strategy, enhancing its technological and market advantages in the in vitro diagnostic field[4]. - The company is actively seizing opportunities for counter-cyclical development in key areas such as respiratory, maternal and child health, blood source, immunology, and sequencing[5]. Performance Forecast and Risks - The financial data in the performance forecast has not been audited by registered accountants and is based on preliminary calculations by the company's financial department[6]. - The company has not identified any significant uncertainties that could affect the accuracy of this performance forecast[6]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change in the official half-year report[7].